Sera Prognostics’ PreTRM® Test and Treat Strategy Benefits Demonstrated by Results of Prospective, Randomized Controlled Intervention Trial Evaluating Clinical Utility August 17, 2021-Sera Prognostics
Sera Prognostics and Anthem, Inc. Announce Commercial Partnership Leveraging Innovative Biomarker Test to Reduce Risk of Preterm Birth May 19, 2021-Sera Prognostics
Evaluation of Health and Economic Benefit of the PreTRM® Test-And-Treat Strategy to Improve Maternal and Infant Health Among Commercially Insured in the US May 18, 2021-Sera Prognostics
Sera Prognostics Appoints Thomas J. Garite, M.D. as Vice President of Clinical Sciences June 24, 2020-Sera Prognostics
Sera Publishes Data Showing PreTRM Test Can Predict Delivery Prior to 32 Weeks June 4, 2020-Sera Prognostics
Sera Prognostics’ PreTrm Biomarker Test Predicts Adverse Pregnancy Outcomes May 28, 2020-Sera Prognostics
